Emina Torlakovic
Research Subjects
Emina Torlakovic has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Goran Torlakovic
From the Department of Pathology (E.T., G.T., J.D.), Norwegian Radium Hospital, Oslo, Norway; and the Department of Laboratory Medicine and Pathology (P.L.N., R.D.B.), Fairview-University Medical Center, University of Minnesota, Minneapolis, Minnesota, U.S.A.
5 shared publications- Jan Delabie
17Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
2 shared publications Aasmund Berner
1 shared publication- Anne Tierens
21Laboratory Medicine Program, University Health Network and University of Toronto, Toronto, Canada
1 shared publication Beata A. Wiatrowska
Department of Pathology, Norwegian Radium Hospital, Oslo, Norway
1 shared publicationBerit Sandstad
Department of Pathology, University Hospital Sarajevo, Bosnia and Herzegovina
1 shared publication
Latest Publications
- 1 October 2004
- Published by Elsevier in Laboratory Investigation
- Vol. 17 (10) , 1251-1258
CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression
- 1 October 2004
- Published by Elsevier in Laboratory Investigation
- Vol. 17 (10) , 1251-1258
CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression
- 1 October 2002
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 26 (10) , 1343-1350
The Value of Anti-Pax-5 Immunostaining in Routinely Fixed and Paraffin-Embedded Sections
Whereas L26 (anti-CD20) is well established as a B-cell marker of high specificity for use in paraffin-embedded tissues and JCB117 (anti-CD79a) is increasingly used, a comparable additional pan-B-cell antibody has hitherto not yet been identified. Here we have studied the use of a novel anti-pan-B-cell marker Pax-5 for use in diagnostic pathology. Pax-5 encodes for BSAP (Pax-5), a B-cell-specific transcription factor, the expression of which is detectable as early as the pro-B-cell stage and subsequently in all further stages of B-cell development until the plasma cell stage where it is downregulated. Pax-5 is essential for B-lineage commitment in the fetal liver, whereas in adult bone marrow this transcription factor is required for progression of B-cell development beyond the early pro-B (pre-BI) cell stage. Among the B-cell genes that are present in early B-cell development and are upregulated by Pax-5 are CD19 and Igα (CD79a). We have tested a commercially available anti-Pax-5 antibody (anti-BSAP, clone 24) in a series of 592 routinely fixed and paraffin wax-embedded biopsies, including lymph nodes, bone marrow, and various other organs containing lymphoid tissues. Pax-5 protein (BSAP) was detected in all cases of precursor and mature B-cell non-Hodgkin lymphomas/leukemias. In addition, in 97% of classic Hodgkin lymphomas, Reed-Sternberg cells expressed Pax-5. However, Pax-5 was not detected in any of the multiple myelomas, solitary plasmacytomas, and 4% of diffuse large B-cell lymphomas. Among those diffuse large B-cell lymphomas not expressing Pax-5 were only those with terminal B-cell differentiation. All T-cell non-Hodgkin lymphomas, including ALCL and lymphoblastic lymphomas and leukemias, were negative. There was a strong association between Pax-5 and CD20 expression. We conclude that anti-Pax-5 is an excellent pan-B and pan-pre-B-cell marker. We have found that anti-Pax-5 is superior to anti-CD20 in the diagnosis of pre-B acute lymphoblastic leukemia and classic Hodgkin lymphoma versus ALCL of T and “null” cell type. It was also useful in differential diagnosis between lymphoplasmacytic lymphoma and plasmacytoma. Even though there is an excellent correlation between CD20 and Pax-5 expression, anti-Pax-5 exceeds the specificity and sensitivity of L26 (anti-CD20) because of its earlier expression in B-cell differentiation and its ability to detect all committed B cells, including classic Hodgkin lymphoma.
- 1 October 2002
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 26 (10) , 1343-1350
The Value of Anti-Pax-5 Immunostaining in Routinely Fixed and Paraffin-Embedded Sections
Whereas L26 (anti-CD20) is well established as a B-cell marker of high specificity for use in paraffin-embedded tissues and JCB117 (anti-CD79a) is increasingly used, a comparable additional pan-B-cell antibody has hitherto not yet been identified. Here we have studied the use of a novel anti-pan-B-cell marker Pax-5 for use in diagnostic pathology. Pax-5 encodes for BSAP (Pax-5), a B-cell-specific transcription factor, the expression of which is detectable as early as the pro-B-cell stage and subsequently in all further stages of B-cell development until the plasma cell stage where it is downregulated. Pax-5 is essential for B-lineage commitment in the fetal liver, whereas in adult bone marrow this transcription factor is required for progression of B-cell development beyond the early pro-B (pre-BI) cell stage. Among the B-cell genes that are present in early B-cell development and are upregulated by Pax-5 are CD19 and Igα (CD79a). We have tested a commercially available anti-Pax-5 antibody (anti-BSAP, clone 24) in a series of 592 routinely fixed and paraffin wax-embedded biopsies, including lymph nodes, bone marrow, and various other organs containing lymphoid tissues. Pax-5 protein (BSAP) was detected in all cases of precursor and mature B-cell non-Hodgkin lymphomas/leukemias. In addition, in 97% of classic Hodgkin lymphomas, Reed-Sternberg cells expressed Pax-5. However, Pax-5 was not detected in any of the multiple myelomas, solitary plasmacytomas, and 4% of diffuse large B-cell lymphomas. Among those diffuse large B-cell lymphomas not expressing Pax-5 were only those with terminal B-cell differentiation. All T-cell non-Hodgkin lymphomas, including ALCL and lymphoblastic lymphomas and leukemias, were negative. There was a strong association between Pax-5 and CD20 expression. We conclude that anti-Pax-5 is an excellent pan-B and pan-pre-B-cell marker. We have found that anti-Pax-5 is superior to anti-CD20 in the diagnosis of pre-B acute lymphoblastic leukemia and classic Hodgkin lymphoma versus ALCL of T and “null” cell type. It was also useful in differential diagnosis between lymphoplasmacytic lymphoma and plasmacytoma. Even though there is an excellent correlation between CD20 and Pax-5 expression, anti-Pax-5 exceeds the specificity and sensitivity of L26 (anti-CD20) because of its earlier expression in B-cell differentiation and its ability to detect all committed B cells, including classic Hodgkin lymphoma.
- Open Access
- 1 September 2002
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 126 (9) , 1136-1137
Follicular Colonization by Follicular Lymphoma
- 1 September 2002
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 126 (9) , 1136-1137
Open AccessFollicular Colonization by Follicular Lymphoma
- Open Access
- 1 July 2002
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 126 (7) , 823-828
CD34/QBEND10 Immunostaining in the Bone Marrow Trephine Biopsy
Context.—The immunohistochemical detection of CD34 protein using QBEND10 antibody in bone marrow trephine biopsies was shown recently to be a precise method for quantitation of blasts and a possibly useful approach in diagnosis and classification of myelodysplastic syndrome. Objectives.—To evaluate CD34+ cells in bone marrow biopsies with various diagnoses and to assess how counts obtained using this method correlate with blast counts obtained by traditional morphologic evaluation of bone marrow smears. Design.—Bone marrow trephine biopsies from 108 adult patients were evaluated by immunohistochemistry using anti-CD34 antibody (QBEND10). CD34+ mononuclear cells were counted and compared with the blast counts in the bone marrow aspirate smears or imprints. CD34+ mononuclear cell clusters and CD34+ megakaryocytes were also recorded. The type of positivity (membranous vs cytoplasmic) and the percentage of CD34+ megakaryocytes were evaluated because the presence of CD34+ megakaryocytes was recently suggested to be present in myelodysplastic syndrome, but not in myeloproliferative disease or nonneoplastic bone marrow. Results.—Six of 24 biopsies with partial involvement by non-Hodgkin lymphoma and 5 of 60 biopsies with reactive changes had 5% to 10% CD34+ mononuclear cells and were associated with lymphocytosis and increased hematogones. The CD34+ mononuclear cell clusters were found only in myelodysplastic syndrome and myeloproliferative disease. The CD34+ megakaryocytes were present in all diagnostic groups. Conclusion.—The number of CD34+ mononuclear cells was often slightly higher than the number of myeloid blasts in the bone marrow smears, probably due to increased hematogones. The presence and the number of CD34+ megakaryocytes do not appear to have diagnostic value, but this finding should be further investigated in relation to clinical parameters.
- 1 July 2002
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 126 (7) , 823-828
Open AccessCD34/QBEND10 Immunostaining in the Bone Marrow Trephine Biopsy
Context.—The immunohistochemical detection of CD34 protein using QBEND10 antibody in bone marrow trephine biopsies was shown recently to be a precise method for quantitation of blasts and a possibly useful approach in diagnosis and classification of myelodysplastic syndrome. Objectives.—To evaluate CD34+ cells in bone marrow biopsies with various diagnoses and to assess how counts obtained using this method correlate with blast counts obtained by traditional morphologic evaluation of bone marrow smears. Design.—Bone marrow trephine biopsies from 108 adult patients were evaluated by immunohistochemistry using anti-CD34 antibody (QBEND10). CD34+ mononuclear cells were counted and compared with the blast counts in the bone marrow aspirate smears or imprints. CD34+ mononuclear cell clusters and CD34+ megakaryocytes were also recorded. The type of positivity (membranous vs cytoplasmic) and the percentage of CD34+ megakaryocytes were evaluated because the presence of CD34+ megakaryocytes was recently suggested to be present in myelodysplastic syndrome, but not in myeloproliferative disease or nonneoplastic bone marrow. Results.—Six of 24 biopsies with partial involvement by non-Hodgkin lymphoma and 5 of 60 biopsies with reactive changes had 5% to 10% CD34+ mononuclear cells and were associated with lymphocytosis and increased hematogones. The CD34+ mononuclear cell clusters were found only in myelodysplastic syndrome and myeloproliferative disease. The CD34+ megakaryocytes were present in all diagnostic groups. Conclusion.—The number of CD34+ mononuclear cells was often slightly higher than the number of myeloid blasts in the bone marrow smears, probably due to increased hematogones. The presence and the number of CD34+ megakaryocytes do not appear to have diagnostic value, but this finding should be further investigated in relation to clinical parameters.
- Open Access
- 1 July 2002
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 126 (7) , 862-863
B-Cell Markers in Lymphocyte Predominance Hodgkin Disease
- 1 July 2002
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 126 (7) , 862-863
Open AccessB-Cell Markers in Lymphocyte Predominance Hodgkin Disease
- 1 November 2001
- Published by Elsevier in The American Journal of Pathology
- Vol. 159 (5) , 1807-1814
The Transcription Factor PU.1, Necessary for B-Cell Development Is Expressed in Lymphocyte Predominance, But Not Classical Hodgkin’s Disease
- 1 November 2001
- Published by Elsevier in The American Journal of Pathology
- Vol. 159 (5) , 1807-1814
The Transcription Factor PU.1, Necessary for B-Cell Development Is Expressed in Lymphocyte Predominance, But Not Classical Hodgkin’s Disease
- 29 October 2001
- Published by Wiley in Diagnostic Cytopathology
- Vol. 25 (5) , 303-308
Cultured anaplastic cell lines as immunocytochemistry controls: A comparison of ThinPrep®‐processed smears and conventional air‐dried cytospins
Cultured anaplastic cell lines with previously characterized phenotypes are considered to be the best positive controls for immunocytochemistry. We assessed the validity of using anaplastic cell line cytospins as positive controls for immunocytochemistry performed on ThinPrep®‐processed clinical samples. We compared ThinPrep®‐processed slides and air‐dried cytospins from cultured anaplastic cell lines for intensity and pattern of staining. Also, antigen preservation was assessed over a 3‐mo period, using a panel of 16 primary antibodies and 12 anaplastic cell lines. A three‐step alkaline phosphatase procedure was used except when in a single instance the EnVision™ method was employed. If appropriately stored, both preparations showed excellent correlation with no decrease in antigenicity during the 3‐mo testing period. ThinPrep®‐processed slides from clinical samples are ideal for immunocytochemistry, because internal negative controls can be performed for each test. We recommend the use of cytospins for positive controls because of the lower cost. Diagn. Cytopathol. 25:303–308, 2001.
- 29 October 2001
- Published by Wiley in Diagnostic Cytopathology
- Vol. 25 (5) , 303-308
Cultured anaplastic cell lines as immunocytochemistry controls: A comparison of ThinPrep®‐processed smears and conventional air‐dried cytospins
Cultured anaplastic cell lines with previously characterized phenotypes are considered to be the best positive controls for immunocytochemistry. We assessed the validity of using anaplastic cell line cytospins as positive controls for immunocytochemistry performed on ThinPrep®‐processed clinical samples. We compared ThinPrep®‐processed slides and air‐dried cytospins from cultured anaplastic cell lines for intensity and pattern of staining. Also, antigen preservation was assessed over a 3‐mo period, using a panel of 16 primary antibodies and 12 anaplastic cell lines. A three‐step alkaline phosphatase procedure was used except when in a single instance the EnVision™ method was employed. If appropriately stored, both preparations showed excellent correlation with no decrease in antigenicity during the 3‐mo testing period. ThinPrep®‐processed slides from clinical samples are ideal for immunocytochemistry, because internal negative controls can be performed for each test. We recommend the use of cytospins for positive controls because of the lower cost. Diagn. Cytopathol. 25:303–308, 2001.